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Abstract The management of patients with breast cancer
during pregnancy is very demanding and it should be better
performed in highly qualified and experienced centers. Refer-
ral to institutes and physicians trained in this special clinical
scenario allows reducing the risk of both overtreating and
undertreating the patients. Moreover, patients can receive
appropriate information regarding safety of treatments without
old-fashioned taboo. The purpose of the current paper is to
discuss the main issues concerning surgical management and
in general locoregional treatment of patients diagnosed with
breast cancer and treated during gestation, focusing on those
women who chose to continue their pregnancy. We cover the
issues regarding type of breast surgery, radiation therapy,
immediate reconstruction during mastectomy, and manage-
ment of the axilla.
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Introduction and general considerations
Breast cancer diagnosed during pregnancy (BCdP), defined as
breast cancer which develops either during or within 1 year
after pregnancy, is expected to become even more common,
since women often delay childbearing to their thirties and
forties when breast cancer rates tend to increase. Some studies
have found that BCdP is more commonly diagnosed at an
advanced stage because of increased breast density, making
clinical examinations and mammography more difficult to
interpret [1–3].
Prognosis is influenced by treatment options, either local or
systemic, which might be limited by the concern of harming
the fetus and conditioned by gestational age. Therefore, it is
important to clarify that most part of therapies can be safely
administered to pregnant patients as well giving the opportu-
nity to the mother to receive optimal treatments [4–6]. Azim
et al. [1] reported in their metaanalysis of pregnancy-
associated breast cancer that there was a poorer breast cancer
outcome for women diagnosed in the postpartum period com-
pared with those diagnosed with breast cancer during preg-
nancy. This is not in contrast with Amant et al. [7] who
reported on the prognosis of women with primary breast
cancer diagnosed during pregnancy and note similar overall
survival compared with general population of non-pregnant
patients. Many studies in the past have considered the two
groups (breast cancer during pregnancy and post-partum
breast cancer) as part of the same condition, and this could
be the reason for the controversial results on prognosis.
Though, the occurrence of BCdP represents a dramat-
ic condition for the patient, her family, and sometimes
her physician mostly if the lattest is not carefully and
specifically trained on this special clinical scenario. In
fact, the management of BCdP requires a collaborative
team effort to provide the best medical options and
most effective psychosocial support.
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The purpose of the current paper is to discuss the main
issues concerning surgical management and in general loco-
regional treatment of patients diagnosed with breast cancer
during pregnancy (BCdP). As treatment of breast cancer dur-
ing lactation does not imply special major problems in terms
of availability of treatments, our paper will focus only on
patients with breast cancer diagnosed and treated during ges-
tation. Moreover, this special clinical scenario is still infre-
quent, and therefore, some of the recommendations may nec-
essarily have only a low level of evidence (expert opinion).
Before treatment, it is important to discuss and inform the
woman and her family about the maternal prognosis and
treatment options as well as the potential impact on pregnancy
and delivery, according to different staging. As interruption of
pregnancy give access to therapies as in a non pregnant
woman, the multidisciplinary team have to discuss differences
with the patients in case of continuation of the pregnancy.
Our considerations will be restricted to those women who
choose to continue their pregnancy, and all the issues related
to voluntary interruption of pregnancy will not be included.
As a general statement, the patients should be made aware that
interruption of pregnancy by itself does not seem to improve
outcome of patients [8].
Breast conserving surgery and the problem of delaying
radiation therapy
Historically, mastectomy was considered the standard surgical
procedure in pregnant patients with breast cancer [9].
Actually, due to a frequent diagnostic delay, patients with
BCdP often present with large tumors requiring radical sur-
gery. Modern studies report a mean diagnostic delay during
pregnancy and lactation ranging from 1 to 3 months with a
median tumor size at diagnosis of 3.5 cm [9]. Nevertheless, in
our opinion, it is important to inform the patient that mastec-
tomy is not mandatory for the treatment of breast cancer just
because of the presence of pregnancy by itself [10, 11].
The published experience on breast conservation is so far
limited, but all the available data seem to go in the same
direction supporting safety and feasibility of breast conserva-
tion with good prognostic results in terms of local control
[12–14]. In the experience of European Institute of Oncology
of Milan [12], tumor size and rate of axillary metastases in
patients with BCdP were lower than in previous reports [13],
probably because of the increased awareness among both
patients and physicians. This earlier stage of presentation
(median tumor size 2.4 cm) enabled a higher rate of breast-
conserving procedures (15 of 21 patients) even though it has
to be pointed out that all the six patients who were diagnosed
during the first trimester opted for termination of pregnancy.
After a short-term median follow-up (24 months), there were
no intra-breast tumor recurrences. Kuerer et al. reported
similar survival rates between patients treated with breast-
conserving surgery and those treated with mastectomy [14].
As a general recommendation, breast conservation can be
safely performed, whenever possible, in women diagnosed
during the third trimester, as radiotherapy can be postponed
until after delivery without major concerns about a possible
detrimental delay.
The concurrent diagnosis of breast cancer and an unexpect-
ed early pregnancy represents the most challenging treatment
scenario. It is considered that abortion is not a therapeutic
procedure in these cases [13], but termination of pregnancy
can be considered in order to facilitate completion of treat-
ment. For patients at the first trimester who desire to continue
the pregnancy, treatment is possible but there is a limited
number of options during the first weeks of gestation. In fact,
chemotherapy is prohibited during the first trimester, and
endocrine treatments are not feasible [13, 15]. Surgery is safe
at any time and during the first trimester as well [16], but
breast conservation performed during a very early gestational
age is associated with a long delay in postoperative radiother-
apy. Unfortunately, there is limited and retrospective experi-
ence published on the delayed radiotherapy after breast con-
servation and its effect on outcome. In a study evaluating 568
patients with T1–T2 N0 breast cancer who underwent lump-
ectomy and radiotherapy without systemic treatment, similar
rate of recurrence was reported in node negative patients when
radiotherapy starts up to 16weeks after definitive surgery after
a median follow-up of 11.2 years [17]. Another retrospective
study reported on 13,907 patients aged 65 years or older with
stage I–II breast cancer who underwent lumpectomy and
radiotherapy taken from the Surveillance, Epidemiology, and
End Results (SEER)–Medicare database. The authors con-
cluded that delays of >3 months were associated with poor
survival, even though older age, black race, advanced stage,
more comorbidities, and being unmarried were associated
with longer time intervals between surgery and RT, and there-
fore, it is not clear whether the association is causal or due to
confounding factors [18]. Chen et al. [19] performed a sys-
tematic review on the relationship between waiting time for
radiotherapy and clinical outcomes with special attention on
local recurrence. In this meta-analysis considering 20 high
quality studies that had adequately controlled for confounding
factors, a significant increase of local failure was demonstrat-
ed with increasing waiting times. The authors subsequently
converted the relative risks derived from the meta-analysis
into estimates of the increment in risk attributable to 1 month
of the waiting time for RT and this translated into an absolute
increase in the risk of local recurrence of 1.0 % per month of
delay of staring RT.
Trying to be practical despite these controversial data, it is
very likely that pregnant patients with breast cancer will
undergo adjuvant chemotherapy after surgery as this is the
only adjuvant possible treatment during gestation. Actually,
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most part of nonpregnant patients undergoing adjuvant che-
motherapy usually receive radiotherapy after more than
6 months, and in these patients, the delay of administration
does not represent an issue of major concern.
Basically, we suggest that in patients at the second or third
trimester, the surgical approach applied to women with BCdP
should not significantly differ from the policy applied to
nonpregnant women, and the delay in administering RT is
probably similar to what happens to nonpregnant patients.
In a patient at the first trimester who wants to continue the
pregnancy and also wishes to conserve the breast, all these
issues have to be carefully discussed, and the patient has to be
informed that a possible increased risk of local recurrence
should be considered, even though this is difficult to quantify
because of the lack of clear data. The patients should also be
reassured that in nonpregnant patients receiving chemothera-
py, radiotherapy is usually given 6 months after surgery.
External beam radiation therapy
Embryonic exposure resulting from breast radiotherapy with a
dose of 0.1 Gy in the first trimester, during organogenesis,
increases the risk of malformations and can cause mental
retardation [20, 21].
The dose to a fetus resulting from tangential breast irradi-
ation, measured using anthropomorphic phantoms simulating
the geometry of a pregnant woman, has been calculated for the
first, second, and third trimester of gestation [20]. The dose
increased as the pregnancy became more advanced, because
of the increased proximity of the fetus to the primary irradia-
tion field. With shielding a 50–75 % dose reduction can be
achieved [22, 23]. These data are applicable for all the X-ray
energies from 4 to 10 MV used for breast radiotherapy. Thus,
during the first and the second trimester of pregnancy, the fetal
irradiation dose seems to be lower than the threshold values
associated organ malformations. During the third trimester,
however, the dose seems to exceed this threshold. In addition,
in utero irradiation at all gestational ages may increase the risk
of cancer during childhood [20]. A conservative estimate of
the lifetime risk of radiation induced by fetal exposure to
0.01 Gy is about one in 1700 cases [22].
Successful radiotherapy of breast cancer during pregnancy
and birth of healthy children has been reported [24–28]. The
short-term fetal outcome following radiotherapy for BCdP has
been recently documented. After a median follow up of
37 months, Luis et al. calculated 13/109 adverse outcomes,
including spontaneous abortions (n=2), perinatal death (n=5),
stillbirth (n=1), hypospadia (n=1), learning problem and sco-
liosis (n=1), sensory hearing loss (n=1), attention deficit
disorder with delayed coordination (n=1), undescended left
testicle, and an uncomplicated ventricular septal defect (n=1)
[27]. Where available (n=4), the estimated fetal dose was
below the threshold dose (<0.1 Gy). Of the 24 patients treated
for breast cancer, 3 had an adverse fetal outcome: 2 perinatal
deaths were described after chest wall/axilla irradiation and
one spontaneous abortion after lumbar spine irradiation
(30 Gy) at 10 weeks of gestation for metastatic disease [29].
Overall, the fetal outcome is poorly documented and it is
difficult to define the role of radiotherapy when an adverse
outcome is noted.
Therefore, radiotherapy is considered relatively safe only
during the first and second trimester of pregnancy but based
on theoretical assumptions and few experiences. Better clini-
cal data are needed and every single case should be discussed
with a patient and by a multidisciplinary team, tailoring as
much as possible every single case [11].
Is partial breast irradiation possible during pregnancy?
The strength and the attractiveness of accelerated partial breast
irradiation (APBI) techniques for breast cancer are reducing
the volume treated, with potential decrease of normal tissue
toxicity, and reducing the treatment time [30]. In response to
the increasing use of APBI off clinical trial several consensus
statements from different panels have been published regard-
ing the appropriate use of partial breast irradiation in nonpreg-
nant breast cancer patients. The National Comprehensive
Cancer Network (NCCN) guidelines published in 2011 [31]
open the possibility to patients to be given APBI according to
criteria identified by American Society for Radiation Oncolo-
gy (ASTRO) consensus for the “suitable” group which in-
cludes only women aged >60 years. Therefore, the application
of APBI remains controversial in young patients with breast
cancer due to the increased local recurrence rate after breast
conservation in this subset of patients. Nevertheless, the issues
concerning on one hand safety and on the other hand the
possible risks of delaying radiotherapy in pregnant patients
with breast cancer make PBI theoretically attractive as an
alternative option.
Electron beam intraoperative radiotherapy (ELIOT) is a
new technique permitting breast radiotherapy to be completed
in a single session. Since ELIOT is associated with much
reduced irradiation to non-target tissues, Galimberti el at.
carried out a study on nonpregnant breast cancer patients to
estimate doses to the uterus during ELIOT [32].
The authors performed in vivo dosimetry with thermolu-
minescence radiation detectors (TLDs) in 15 premenopausal
patients receiving ELIOT to the breast (prescribed dose
21 Gy) using two mobile linear accelerators. The TLDs were
positioned subdiaphragmatically on the irradiated side, at the
medial pubic position, and within the uterus. A shielding
apron (2-mm lead equivalent) was placed over the viscera
from the subcostal to the subpubic region. TLDs showed
mean doses of 0.37 Gy (range 0.01–0.85 Gy) at
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subdiaphragm, 0.09 Gy (range 0.003–0.02 Gy) pubic, and
0.17 Gy (range 0.06–0.32 Gy) in utero, for beam energies in
the range 5–9MeV. These findings indicate that ELIOTwith a
mobile linear accelerator and shielding apron would be safe
for the fetus, as doses of a few Gy are not associated with
measurable increased risk of fetal damage, and the threshold
dose for deterministic effects is estimated at 0.1–0.2 Gy.
Intraoperative radiotherapy could reduce fetal dose, and for
this result so attractive for pregnant management, there are
limitations and doubts about the efficacy of PBI in young
patients with breast cancer. Nevertheless, we believe that this
might be a further option to offer to pregnant patients with a
small breast cancer diagnosed at a very early gestational age
and who are motivated to continue the pregnancy after a
thorough explanation of a possible increase in local recurrence
if compared to WBRT. Always an estimation of the fetal
exposure should be assessed by a physicist in order to assess
fetal safety.
Mastectomy and immediate breast reconstruction
In the recent past, mastectomy has been considered the treat-
ment of choice for pregnant patients with breast cancer [9]. To
date, despite breast conservation can be considered, a consid-
erable proportion of patients to date still require a mastectomy
due to the large tumor size at presentation.
In 2010, a European Consensus on the management of
breast cancer during pregnancy discouraged immediate
breast reconstruction during pregnancy due to lack of
data and recommended prosthetic implant-based recon-
struction after delivery [11]. In fact, at the moment, there
are no available data concerning immediate breast recon-
struction (IBR) in pregnant patients undergoing mastec-
tomy for breast cancer. Nevertheless, it is well known
that IBR decreases the psychological impact of mutila-
tion, provides superior esthetic outcome and better pa-
tient and physician satisfaction compared to delayed re-
construction [33–35].
Therefore, the obvious advantages of immediate breast
reconstruction lead us to explore the possibility to consider
an IBR whenever possible even in pregnant patients, and in
our view, pregnant breast cancer patients should not be denied
by definition the opportunity to undergo immediate breast
reconstruction after mastectomy. At the European Institute of
Oncology, we usually suggest a tissue expander which is a
straightforward technique not significantly increasing operat-
ing time and risk of complications. Lohsiriwat et al. [36]
reported the first analysis of 78 patients who underwent im-
mediate breast reconstruction with expander following mas-
tectomy for breast cancer diagnosed during pregnancy de-
scribing an excellent pregnancy outcomes without obstetrical
complications after surgery. Moreover, the unpredictable
physiologic changes of the breast during and after pregnancy,
makes not suitable IBR with definitive implant and contralat-
eral reshaping. IBR by autologous tissue should not be con-
sidered for the long operative time and increased risk of blood
loss and postoperative complications.
Sentinel lymph node biopsy
After initial concern for a safety issue, it is now widely agreed
that sentinel lymph node biopsy (SLNB) for staging of the
regional lymph nodes can be performed safely during preg-
nancy [37, 38].
In 2000, Nicklas and Baker [39] suggested that SLNB
can be safely performed in pregnancy since the entire
radioisotope injected (13.5 to16 MBq of double-filtered
99mTc sulfur colloid) remains trapped at the injection site
on the breast or within the lymphatics. Morita et al. [40]
stated that receiving a whole-body dose from activity 13.5
to 16 MBq in the breast, the dose of radiation exposure to
the unborn child would be exceedingly low. Some authors
[39, 41, 42] reported that the estimated absorbed dose to
the fetus/embryo per unit activity of 99mTc-HSA admin-
istered intravenously to the mother is 5.1 mGy/MBq. Do-
simetric evaluations reported in the literature as well as
data from a simulation study gave evidence of negligible
risks to the fetus [43]. Gentilini et al. performed a simula-
tion in vivo study in order to investigate safety of
lymphoscintigraphy in terms of radiation risk and estimate
of the possible absorbed doses to the fetus with a single
peritumoral injection of 99mTc-labeled human albumin
colloid particles (99mTc-HSA nanocolloids) in a volume
of 0.2 ml 16–18 h before the surgical intervention. The
injected activity was found to be concentrated only in the
injection site and in the lymph nodes, demonstrating neg-
ligible irradiation to other tissues, organs, and the absence
of radiotracer uptake in the pelvis after 15 min. In 23 of 26
nonpregnant patients studied, all absorbed dose measure-
ments were lower than the sensitivity of the thermolumi-
nescent dosimeters used (<10 mGy); in the remaining three
patients, the absorbed doses at the level of epigastrium,
umbilicus, and hypogastrium ranged from 0.03 to 0.32 Gy.
The total activity excreted in the urine within the first 16 h
(time between injection and operation) was <2 % of the
injected activity. The biological pharmacokinetic data
showed that a very small amount of the injected activity
is circulating in the blood pool and excreted by the urinary
system confirming that the level of radioactivity in the
body is absolutely negligible at each time point studied
after the administration, proving that there is a negligible
risk to the fetus [37]. This level is far less than the National
Council on Radiation Protection and Measurements limit
to pregnant women [44].
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Experiences derived from treatment of melanoma or breast
cancer who underwent lymphatic mapping during pregnancy
have not shown birth defects or discernible malformations in
born [38].
Gentilini et al. reported data from 12 pregnant patients with
breast cancer who underwent lymphoscintigraphy and SLNB,
focusing on the outcomes of the pregnancies. Eleven babies
were born with normal weight and no malformations and after
a median follow up of 32 months (6–83 months), were doing
well. One baby had a diagnosis of ventricular septal defect
(VSD) and was operated on at the age of 3 months because of
the onset of cardiac failure. However, VSD was demonstrated
with ultrasound before the lymphoscintigraphy procedure and
therefore cannot be attributed to the injection of the radioac-
tive tracer.
As a practical recommendation, it is advisable to inject
colloid in the morning (1-day protocol) in order to reduce time
and dose of radiation exposure.
Blue dye should not be used during pregnancy as its use
has a possible risk of an allergic or anaphylactic maternal
reaction, which can be harmful for the fetus [43]. Isosulfan
blue has a possible risk (1 %) of an allergic and anaphylactic
reaction, which can increase the risk of harm to the fetus.
Methylene blue is contraindicated in the pregnant patients
during first trimester because of known teratogenic effect of
jejunal atresia due to of vasoconstrictive effects in blocking
nitric oxide [43].
Concluding remarks
Surgery can be safely performed during pregnancy and during
the first trimester as well. Mastectomy should not be recom-
mended just because of the pregnancy itself, and breast con-
servation should be discussed whenever possible. In patients
operated during the third or even the second trimester, radia-
tion therapy can be safely postponed after delivery [11]. The
risk of a possible too long delay of radiation therapy in case of
surgery performed at a very early gestational age should be
taken into account and all the options should be considered
according to patient’s preference. However, virtually, all pa-
tients need adjuvant chemotherapy, bridging the gap between
surgery and radiotherapy. Partial breast irradiation, especially
with electrons (ELIOT) might be an interesting option in the
future even if at the moment there is lack of data and some
doubts might be raised regarding treatment of young patients
in terms of increased risk of local recurrence. For those pa-
tients requiring mastectomy, an immediate breast reconstruc-
tion with tissue expander can be performed as it does not
excessively increase operative time and risk of complications.
Lymphoscintigraphy and sentinel node biopsy by the use of
99mTc is safe in pregnant patients as well.
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